COGNOSCI INC

Basic Information

2 DAVIS DR
RESEARCH TRIANGLE PARK, NC, 27709-0000

Company Profile

n/a

Additional Details

Field Value
DUNS: 141881727
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 4


  1. Inhibitor #2 of Protein Phosphatase 2A (I2PP2A) and Asthma

    Amount: $268,220.00

    DESCRIPTION (provided by applicant): Over 24 million Americans suffer from asthma, which has become a chronic inflammatory disease of the airways characterized by reversible airflow obstruction and br ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Novel Drug VS-105 for Treatment of Osteoporosis

    Amount: $273,242.00

    DESCRIPTION (provided by applicant): Investigational Safety and Toxicity Studies of Subcutaneous COG1410 for Alzheimer's Disease: A Therapeutic Based upon Apolipoprotein-E That is Not Targeted to ...

    SBIR Phase I 2013 Department of Health and Human Services
  3. CDX-301 and Plerixafor Combination in Stem Cell Mobilization for Transplantation

    Amount: $225,067.00

    DESCRIPTION (provided by applicant): Diabetic peripheral neuropathy (DPN) is one of the most common and devastating complications of diabetes mellitus, affecting more than 50% of diabetic patients, an ...

    SBIR Phase I 2013 Department of Health and Human Services
  4. Novel COG Compounds to Treat Asthma

    Amount: $261,824.00

    DESCRIPTION (provided by applicant): Our overall goal is to market a COG compound (aka. apoE-mimetic peptides) for the treatment of patients with asthma. Cognosci has discovered, patented and publish ...

    SBIR Phase I 2012 Department of Health and Human Services
  5. Sustained Release Formulation for Treatment of Autoimmune Disease MS

    Amount: $279,054.00

    DESCRIPTION (provided by applicant): Multiple sclerosis (MS) is an inflammatory autoimmune disease in young adults, affecting more than 530,000 people in the United States and approximately 2 million ...

    SBIR Phase I 2011 Department of Health and Human Services
  6. High Throughput Screen for Novel Anti-Rheumatic Compounds

    Amount: $333,305.00

    DESCRIPTION (provided by applicant): Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease targeting the synovium, the tissue that lines the joints. It is associated wi ...

    SBIR Phase I 2010 Department of Health and Human Services
  7. Therapeutic for Intracerebral Hemorrhage

    Amount: $258,584.00

    DESCRIPTION (provided by applicant): Intracerebral hemorrhage (ICH) is a devastating and relatively common disease affecting as many as 50,000 people annually in the United States alone. ICH remains ...

    SBIR Phase I 2009 Department of Health and Human Services
  8. Novel Restorative Therapy for Spinal Cord Injury

    Amount: $1,216,437.00

    DESCRIPTION (provided by applicant): Novel Restorative Therapy for Spinal Cord Injury Spinal cord injury (SCI) is a devastating traumatic CNS disorder that significantly disables about 253,000 America ...

    SBIR Phase II 2009 Department of Health and Human Services
  9. Neurorestorative Strategy for Chemotherapy-induced Peripheral Neuropathy

    Amount: $326,711.00

    DESCRIPTION (provided by applicant): Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting side effect of many commonly used chemotherapeutic agents, including platinum drugs and ...

    SBIR Phase I 2009 Department of Health and Human Services
  10. Novel Screen for Targeted CLL Therapeutics

    Amount: $289,114.00

    DESCRIPTION (provided by applicant): Of the nearly 84,000 cases of leukemia in the Western world, B-cell chronic lymphocytic leukemia (B-CLL) is the most common and accounts for approximately 30% of a ...

    SBIR Phase I 2009 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government